File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.18632/oncotarget.3659
- Scopus: eid_2-s2.0-84934324649
- PMID: 25912308
- WOS: WOS:000359010700020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis
Title | Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis |
---|---|
Authors | |
Keywords | BRCA1 Cisplatin sensitivity MFF MiR-593-5p Mitochondrial fission |
Issue Date | 2015 |
Publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html |
Citation | Oncotarget, 2015, v. 6 n. 17, p. 14885-14904 How to Cite? |
Abstract | Cisplatin has been widely employed as a cornerstone chemotherapy treatment for a wide spectrum of solid neoplasms; increasing tumor responsiveness to cisplatin has been a topic of interest for the past 30 years. Strong evidence has indicated that mitochondrial fission participates in the regulation of apoptosis in many diseases; however, whether mitochondrial fission regulates cisplatin sensitivity remains poorly understood. Here, we show that MFF mediated mitochondrial fission and apoptosis in tongue squamous cell carcinoma (TSCC) cells after cisplatin treatment and that miR-593-5p was downregulated in this process. miR-593-5p attenuated mitochondrial fission and cisplatin sensitivity by targeting the 3’ untranslated region sequence of MFF and inhibiting its translation. In exploring the underlying mechanism of miR-593-5p downregulation, we observed that BRCA1 transactivated miR-593-5p expression and attenuated cisplatin sensitivity in vitro. The BRCA1-miR-593-5p-MFF axis also affected cisplatin sensitivity in vivo. Importantly, in a retrospective analysis of multiple centers, we further found that the BRCA1-miR-593-5p-MFF axis was significantly associated with cisplatin sensitivity and the survival of patients with TSCC. Together, our data reveal a model for mitochondrial fission regulation at the transcriptional and post-transcriptional levels; we also reveal a new pathway for BRCA1 in determining cisplatin sensitivity through the mitochondrial fission program. |
Persistent Identifier | http://hdl.handle.net/10722/211689 |
ISSN | 2016 Impact Factor: 5.168 2023 SCImago Journal Rankings: 0.789 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fan, S | - |
dc.contributor.author | Liu, B | - |
dc.contributor.author | Sun, L | - |
dc.contributor.author | Lv, XB | - |
dc.contributor.author | Lin, Z | - |
dc.contributor.author | Chen, W | - |
dc.contributor.author | Tang, Q | - |
dc.contributor.author | Wang, Y | - |
dc.contributor.author | Su, Y | - |
dc.contributor.author | Jin, S | - |
dc.contributor.author | Zhang, D | - |
dc.contributor.author | Zhong, J | - |
dc.contributor.author | Li, Y | - |
dc.contributor.author | Wen, B | - |
dc.contributor.author | Zhang, Z | - |
dc.contributor.author | Yang, P | - |
dc.contributor.author | Zhou, B | - |
dc.contributor.author | Liang, Q | - |
dc.contributor.author | Yu, X | - |
dc.contributor.author | Zhu, Y | - |
dc.contributor.author | Hu, P | - |
dc.contributor.author | Chu, J | - |
dc.contributor.author | Huang, W | - |
dc.contributor.author | Feng, Y | - |
dc.contributor.author | Peng, H | - |
dc.contributor.author | Huang, Q | - |
dc.contributor.author | Song, E | - |
dc.contributor.author | Li, J | - |
dc.date.accessioned | 2015-07-21T02:07:59Z | - |
dc.date.available | 2015-07-21T02:07:59Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Oncotarget, 2015, v. 6 n. 17, p. 14885-14904 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/10722/211689 | - |
dc.description.abstract | Cisplatin has been widely employed as a cornerstone chemotherapy treatment for a wide spectrum of solid neoplasms; increasing tumor responsiveness to cisplatin has been a topic of interest for the past 30 years. Strong evidence has indicated that mitochondrial fission participates in the regulation of apoptosis in many diseases; however, whether mitochondrial fission regulates cisplatin sensitivity remains poorly understood. Here, we show that MFF mediated mitochondrial fission and apoptosis in tongue squamous cell carcinoma (TSCC) cells after cisplatin treatment and that miR-593-5p was downregulated in this process. miR-593-5p attenuated mitochondrial fission and cisplatin sensitivity by targeting the 3’ untranslated region sequence of MFF and inhibiting its translation. In exploring the underlying mechanism of miR-593-5p downregulation, we observed that BRCA1 transactivated miR-593-5p expression and attenuated cisplatin sensitivity in vitro. The BRCA1-miR-593-5p-MFF axis also affected cisplatin sensitivity in vivo. Importantly, in a retrospective analysis of multiple centers, we further found that the BRCA1-miR-593-5p-MFF axis was significantly associated with cisplatin sensitivity and the survival of patients with TSCC. Together, our data reveal a model for mitochondrial fission regulation at the transcriptional and post-transcriptional levels; we also reveal a new pathway for BRCA1 in determining cisplatin sensitivity through the mitochondrial fission program. | - |
dc.language | eng | - |
dc.publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html | - |
dc.relation.ispartof | Oncotarget | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | BRCA1 | - |
dc.subject | Cisplatin sensitivity | - |
dc.subject | MFF | - |
dc.subject | MiR-593-5p | - |
dc.subject | Mitochondrial fission | - |
dc.title | Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis | - |
dc.type | Article | - |
dc.identifier.email | Su, Y: richsu@hku.hk | - |
dc.identifier.authority | Su, Y=rp01916 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.18632/oncotarget.3659 | - |
dc.identifier.pmid | 25912308 | - |
dc.identifier.scopus | eid_2-s2.0-84934324649 | - |
dc.identifier.hkuros | 245348 | - |
dc.identifier.volume | 6 | - |
dc.identifier.issue | 17 | - |
dc.identifier.spage | 14885 | - |
dc.identifier.epage | 14904 | - |
dc.identifier.isi | WOS:000359010700020 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1949-2553 | - |